# Madrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026
Canonical URL: https://biopharmsignal.com/news/MDGL/madrigal-pharmaceuticals-to-participate-in-the-47th-annual-global-goldman-sachs--472ea0f3
Ticker: MDGL
Company: Madrigal
Source: Madrigal
Published: 2026-06-03 12:00 EST
## Summary

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in...

## Article Body
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the 47 th Annual Global Goldman Sachs Health Care Conference 2026 on Wednesday, June 10, 2026, at 11:20 A.M. EDT.

The presentation will be webcast live and may be accessed here or by visiting Madrigal’s Investor Relations Events and Presentations page . A replay of the webcast will be available after the event.

About Madrigal Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra was the first medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com and follow us on LinkedIn .

Investor Contact Tina Ventura, IR@madrigalpharma.com

Media Contact Christopher Frates, media@madrigalpharma.com
## Recent Company News
- 2026-07-21 20:05 EST — [Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/MDGL/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-list-004ea5d8) — Source: Madrigal
- 2026-07-16 12:00 EST — [Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026](https://biopharmsignal.com/news/MDGL/madrigal-pharmaceuticals-to-release-second-quarter-2026-financial-results-and-ho-8492a4a5) — Source: Madrigal
- 2026-07-13 12:00 EST — [Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio](https://biopharmsignal.com/news/MDGL/madrigal-pharmaceuticals-announces-three-new-resmetirom-patents-strengthening-ip-f27ea704) — Source: Madrigal
- 2026-07-06 20:05 EST — [Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/MDGL/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-list-cb20d3fa) — Source: Madrigal
- 2026-06-22 20:05 EST — [Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/MDGL/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-list-bbbe1357) — Source: Madrigal
## Related News
- 2026-07-27 15:00 EST — CAPR — [Capricor Comments on Briefing Materials Ahead of July 29 FDA Advisory Committee Meeting for Deramiocel](https://biopharmsignal.com/news/CAPR/capricor-comments-on-briefing-materials-ahead-of-july-29-fda-advisory-committee--3a3054d7)
- 2026-07-27 14:55 EST — GSK — [ViiV Healthcare’s 2-drug regimen Dovato is as effective as 3-drug regimen Biktarvy in first-of-its-kind head-to-head study in treatment-naïve adults living with HIV](https://biopharmsignal.com/news/GSK/viiv-healthcare-s-2-drug-regimen-dovato-is-as-effective-as-3-drug-regimen-biktar-781cde81)
- 2026-07-27 13:00 EST — SPRO — [Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer](https://biopharmsignal.com/news/SPRO/spero-therapeutics-appoints-debra-jeske-zack-m-d-ph-d-as-chief-medical-officer-81a269de)
- 2026-07-27 12:32 EST — ICCM — [IceCure Medical Kicks Off its Post-Marketing "ChoICE" Study for the Low-Risk Breast Cancer Treatment at First U.S Clinical Site](https://biopharmsignal.com/news/ICCM/icecure-medical-kicks-off-its-post-marketing-choice-study-for-the-low-risk-breas-9de814e1)
- 2026-07-27 12:10 EST — VERU — [Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss](https://biopharmsignal.com/news/VERU/veru-announces-full-enrollment-for-phase-2b-plateau-clinical-trial-of-enobosarm--ce89119d)